OpGen (NASDAQ:OPGN) Now Covered by StockNews.com

Research analysts at StockNews.com began coverage on shares of OpGen (NASDAQ:OPGN) in a report released on Wednesday. The brokerage set a “sell” rating on the medical research company’s stock.

OpGen Trading Up 4.8 %

Shares of NASDAQ:OPGN opened at $1.73 on Wednesday. The business’s 50-day simple moving average is $1.99 and its 200 day simple moving average is $3.24. OpGen has a one year low of $1.61 and a one year high of $13.40.

OpGen (NASDAQ:OPGN) last posted its quarterly earnings data on Monday, August 19th. The medical research company reported ($1.18) earnings per share (EPS) for the quarter. The firm had revenue of $0.03 million for the quarter.

Hedge Funds Weigh In On OpGen

A hedge fund recently bought a new stake in OpGen stock. Chase Investment Counsel Corp purchased a new position in OpGen, Inc. (NASDAQ:OPGN) during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund purchased 331,890 shares of the medical research company’s stock, valued at approximately $230,000. Chase Investment Counsel Corp owned approximately 2.63% of OpGen as of its most recent filing with the Securities & Exchange Commission. 2.68% of the stock is owned by hedge funds and other institutional investors.

OpGen Company Profile

OpGen, Inc, a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits.